Citius Oncology Inc (CTOR)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-11-05
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-11-05
QuarterlyIQ Insights · CTOR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and its industry peers have been missing lately. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 3 industry peers
CTOR — General Counsel transition
Dated 2026-08-12
Director — Jonathan Peri: The filing describes the appointment of a new independent director to fill an expanded board seat, which is a standard governance action and not a departure of senior management.
Why it matters: The company reported a need for more funds to support operations. Its latest supplied cash figure was $16.6 million at June 30, 2026.
Worry ifA filing reports new funding that supports at least 12 months of operations, or states a longer cash runway.
Less concerning ifA filing reports less than 12 months of cash, or warns that it may not fund operations for the next 12 months.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$302 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $941 loss on $10,000 · 9.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,994 loss on $10,000 · 69.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.